Attached files
| file | filename |
|---|---|
| S-1 - S-1 - Athira Pharma, Inc. | atha-s1.htm |
| EX-10.9 - AMENDED AND RESTATED STANDARD EXCLUSIVE LICENSE AGREEMENT WITH SUBLICENSING TERM - Athira Pharma, Inc. | atha-ex109_529.htm |
| EX-10.1 - INDEMNIFICATION AGREEMENT - Athira Pharma, Inc. | atha-ex101_530.htm |
| EX-4.4 - WARRANT TO PURCHASE COMMON STOCK - Athira Pharma, Inc. | atha-ex44_9.htm |
| EX-4.3 - WARRANT TO PURCHASE SERIES B PREFERRED STOCK - Athira Pharma, Inc. | atha-ex43_7.htm |
Exhibit 23.1
Consent of Ernst and Young, LLP, Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption “Experts” and to the use of our report dated July 24, 2020, in the Registration Statement (Form S-1) and related Prospectus of Athira Pharma, Inc. for the registration of its common stock.
/s/ Ernst & Young LLP
Seattle, Washington
August 26, 2020